PBC患者UDCA治疗1年后生化应答与5年肝衰竭和死亡风险相关
Response to Standard PBC Treatment at 1 Year Linked to Lower Long-Term Risks
一项基于TriNetX美国研究网络的倾向匹配队列研究显示,原发性胆汁性胆管炎(PBC)患者在熊去氧胆酸(UDCA)治疗12个月后,达到生化应答标准(ALP≤130 U/L且胆红素≤1.0 mg/dL)的患者5年肝衰竭累积发生率较非应答者更低(10.2% vs 17.8%。
研究显示UDCA治疗1年后生化应答与较低肝衰竭及死亡风险相关,可为临床随访决策提供参考。
— "Response predicts outcomes in real-world care, and nonresponders carry a risk," researcher says
November 12, 2026 • 2 min read
A biochemical response to ursodeoxycholic acid (UDCA) at 12 months was associated with lower 5-year risks of hepatic decompensation and mortality in patients with primary biliary cholangitis (PBC), a propensity-matched landmark cohort study suggested.
Among patients considered to be responders -- defined as an alkaline phosphatase (ALP) level ≤130 U/L and a bilirubin level ≤1.0 mg/dL -- the 5-year cumulative incidence of hepatic decompensation was 10.2% versus 17.8% among nonresponders (HR 0.60, 95% CI 0.51-0.70, P<0.001), reported EzzElDien A. Ibrahim, MD, MSc, of the University of Missouri in Columbia, at the American Association for the Study of Liver Diseases annual meeting in Denver.
In addition, the cumulative incidence of 5-year all-cause mortality was 12.2% among responders versus 16.3% for nonresponders (HR 0.74, 95% CI 0.65-0.84, P<0.001).
Other clinical outcomes also trended in favor of or significantly favored responders:
- Liver transplant (HR 0.82, 95% CI 0.66-1.01, P=0.062)
- Hepatocellular carcinoma (HR 0.85, 95% CI 0.64-1.14, P=0.282)
- Second-line PBC therapy (HR 0.21, 95% CI 0.17-0.27, P<0.001)
"Response predicts outcomes in real-world care, and nonresponders carry a risk," Ibrahim said. "We can check ALP and bilirubin at 1 year on UDCA," and at that point, clinicians should consider "escalating nonresponders without delay."
UDCA is the first-line treatment for PBC, a rare and chronic autoimmune disease of the bile ducts, "and it ... works," Ibrahim noted.
An international cohort study that included 3,902 patients from the Global PBC Study Group database showed that after inverse probability treatment weighting, the 10-year cumulative liver transplant-free survival rate was 79.7% among UDCA-treated patients and 60.7% among untreated patients, with UDCA treatment resulting in a statistically significantly reduced risk of liver transplant or death (HR 0.46, 95% CI 0.40-0.52, P<0.001).
However, 20% to 40% of patients do not respond biochemically to UDCA at 12 months. In 2024, seladelpar (Livdelzi) and elafibranor (Iqirvo) were granted accelerated approval for patients with PBC who either did not respond to UDCA or were intolerant to the treatment.
While a number of criteria such as the PARIS criteria link 12-month response to UDCA to outcomes, Ibrahim said real-world validation in routine care for 5-year clinical endpoints -- such as decompensation and death -- is limited.
This explains "why this study matters," he noted.
For this study, Ibrahim and colleagues used the TriNetX U.S. Research Network that includes data on 147.5 million patients from 112 health systems.
They included matched cohorts of 2,911 patients with PBC. Mean age was 61.3, 87% were women, 77% were white, 34% had a cirrhosis code, 14% had portal hypertension, and mean albumin level was 3.86-3.91 g/dL.
Responders and nonresponders to UDCA were categorized based on propensity score matching of 29 covariates that included demographics, liver and mental health comorbidities, alanine aminotransferase levels, aspartate aminotransferase levels, platelet counts, albumin levels, and international normalized ratio.
Ibrahim acknowledged that the study had a number of limitations, including the fact that PBC was defined by codes and not by a positive anti-mitochondrial antibody test or histology. In addition, there was no access to UDCA dose or adherence data, and there were a limited number of 5-year events for the liver transplant and hepatocellular carcinoma analyses.
来源:MedPage Today · medpagetoday.com